Genetic Information

Gene & Transcript Details

Gene
ATM
Transcript
NM_000051.4 MANE Select
Total Exons
Reference Sequence
NC_000011.9
Alternative Transcripts
IDStatusDetails
NM_000051.3 RefSeq Select 13147 nt | 386–9556
NM_000051.4 MANE Select 12915 nt | 151–9321

Variant Details

HGVS Notation
NM_000051.4:c.6808-11T>G
Protein Change
?
Location
Exon 46 (Exon 46 of )
46
5'Exon Structure3'
Functional Consequence
Loss of Function
Alternate Identifiers

Clinical & Population Data

Population Frequency

gnomAD
Global Frequency
0.0 in 100,000
Extremely Rare
ACMG Criteria Applied PM2
This variant is absent or extremely rare in population databases (PM2 criteria applies).

ClinVar

Open
Classification
Unknown
0 publications
Clinical Statement

""

COSMIC Somatic Evidence

Open
COSMIC ID
Recurrence
0 occurrences
PM1 Criteria
Not Applied
COSMIC Database Preview
COSMIC Preview
Accessing full COSMIC database details requires institutional login or subscription.

Functional Impact & Domains

Functional Domain

Hotspot Status
Not a hotspot
Domain Summary
This variant is not located in a mutational hotspot or critical domain.
Related Variants in This Domain
No evidence of other pathogenic variants at this position in gene ATM.

Functional Studies & Therapeutic Relevance

Functional Summary

The ATM 6808-11T>G variant has not been functionally characterized.

Database Previews
OncoKB
OncoKB Preview
JAX-CKB
JAX-CKB Preview

Click on previews to view full database entries. External databases may require institutional access.

Computational Analysis

Pathogenicity Predictions

SpliceAI
Predictor Consensus
Mixed/VUS
PP3 Applied
No
REVEL Score
0.0
Threshold: ≥0.75 = PP3 applied

SpliceAI Scores

Window: ±500bp
Effect Type Score Position
- Acceptor Loss (AL) 0.21 11 bp
- Donor Loss (DL) 0.07 178 bp
+ Acceptor Gain (AG) 0.01 44 bp
+ Donor Gain (DG) 0.0 11 bp
High impact (≥0.5) Medium impact (0.2-0.49) Low impact (<0.2)

VCEP Guidelines

Applied ACMG/AMP Criteria (VCEP Specific)

Filter Criteria:
PVS1

PVS1 (Not Applied)

According to VCEP guidelines: ATM PVS1 Decision Tree. The rule states: apply PVS1 only for null variants (nonsense, frameshift, canonical splice +1/2) in ATM where LOF is known mechanism. The evidence for this variant shows: c.6808-11T>G is an intronic change outside the canonical ±1/2 splice sites with no demonstrated LOF. Therefore, this criterion is not applied because the variant does not meet the null variant definition.

PS1

PS1 (Not Applied)

According to VCEP guidelines: PS1 applies to protein changes identical to established pathogenic variants when splicing is ruled out. The evidence for this variant shows: it is intronic with no predicted protein change. Therefore, this criterion is not applied because there is no protein alteration.

PS2

PS2 (Not Applied)

According to standard ACMG guidelines: PS2 requires confirmed de novo occurrence. The evidence for this variant shows: no de novo data are available. Therefore, this criterion is not applied due to lack of de novo evidence.

PS3

PS3 (Not Applied)

According to VCEP guidelines: PS3 applies when well‐validated functional assays show a damaging effect. The evidence for this variant shows: no functional characterization exists for c.6808-11T>G. Therefore, this criterion is not applied because functional data are missing.

PS4

PS4 (Not Applied)

According to standard ACMG guidelines: PS4 requires significant case-control or segregation data. The evidence for this variant shows: no case-control or patient counting data. Therefore, this criterion is not applied due to absence of prevalence data.

PM1

PM1 (Not Applied)

According to standard ACMG guidelines: PM1 applies to variants in mutational hot spots or critical domains. The evidence for this variant shows: location and domain impact are unknown. Therefore, this criterion is not applied because no critical domain involvement is established.

PM2

PM2 (Supporting)

According to VCEP guidelines: PM2 supporting strength when frequency ≤0.001% in a single subpopulation. The rule states: "Frequency ≤.001% if n=1 in a single sub population..." The evidence for this variant shows: c.6808-11T>G is absent from gnomAD (0% frequency). Therefore, this criterion is applied at Supporting strength because the variant is extremely rare/absent in controls.

PM3

PM3 (Not Applied)

According to VCEP guidelines: PM3 applies when variant observed in trans with a pathogenic variant in recessive disorder. The evidence for this variant shows: no information on trans observations. Therefore, this criterion is not applied due to lack of segregation data.

PM4

PM4 (Not Applied)

According to VCEP guidelines: PM4 applies to in-frame indels or stop-loss variants. The evidence for this variant shows: it is intronic without predicted in-frame change. Therefore, this criterion is not applied.

PM5

PM5 (Not Applied)

According to VCEP guidelines: PM5 supporting applies to novel missense or splice variants with PTC upstream of p.Arg3047. The evidence for this variant shows: no PTC creation or known missense position. Therefore, this criterion is not applied.

PM6

PM6 (Not Applied)

According to standard ACMG guidelines: PM6 applies to presumed de novo without confirmation. The evidence for this variant shows: no de novo data. Therefore, this criterion is not applied.

PP1

PP1 (Not Applied)

According to standard ACMG guidelines: PP1 applies with cosegregation in multiple affected family members. The evidence for this variant shows: no segregation data. Therefore, this criterion is not applied.

PP2

PP2 (Not Applied)

According to standard ACMG guidelines: PP2 applies to missense variants in genes with low benign missense rate. The evidence for this variant shows: intronic location and no missense effect. Therefore, this criterion is not applied.

PP3

PP3 (Not Applied)

According to VCEP guidelines: PP3 supporting requires REVEL >0.7333 or at least one in silico predictor showing splicing impact. The evidence for this variant shows: CADD score 3.19, SpliceAI max 0.21 (below impact threshold). Therefore, this criterion is not applied because computational predictions do not support a deleterious effect.

PP4

PP4 (Not Applied)

According to standard ACMG guidelines: PP4 applies when phenotype is highly specific for gene. The evidence for this variant shows: no patient phenotype data. Therefore, this criterion is not applied.

PP5

PP5 (Not Applied)

According to standard ACMG guidelines: PP5 applies when a reputable source classifies variant as pathogenic. The evidence for this variant shows: absent from ClinVar. Therefore, this criterion is not applied.

BA1

BA1 (Not Applied)

According to standard ACMG guidelines: BA1 applies when allele frequency >5%. The evidence for this variant shows: 0% frequency. Therefore, this criterion is not applied.

BS1

BS1 (Not Applied)

According to standard ACMG guidelines: BS1 applies when allele frequency is greater than expected for disorder. The evidence for this variant shows: absent from population databases. Therefore, this criterion is not applied.

BS2

BS2 (Not Applied)

According to standard ACMG guidelines: BS2 applies when variant observed in healthy adult for dominant disorders. The evidence for this variant shows: no such observations. Therefore, this criterion is not applied.

BS3

BS3 (Not Applied)

According to VCEP guidelines: BS3 applies when functional assays show rescue of ATM function. The evidence for this variant shows: no functional rescue data. Therefore, this criterion is not applied.

BS4

BS4 (Not Applied)

According to standard ACMG guidelines: BS4 applies with non-segregation in affected family members. The evidence for this variant shows: no segregation data. Therefore, this criterion is not applied.

BP1

BP1 (Not Applied)

According to standard ACMG guidelines: BP1 applies to missense variants in genes where only truncating variants cause disease. The evidence for this variant shows: intronic location. Therefore, this criterion is not applied.

BP2

BP2 (Not Applied)

According to VCEP guidelines: BP2 applies when variant observed in trans with a pathogenic variant in recessive disorder. The evidence for this variant shows: no such observations. Therefore, this criterion is not applied.

BP3

BP3 (Not Applied)

According to standard ACMG guidelines: BP3 applies to in-frame indels in repetitive regions. The evidence for this variant shows: an intronic SNV. Therefore, this criterion is not applied.

BP4

BP4 (Supporting)

According to standard ACMG guidelines: BP4 applies when multiple computational lines suggest no impact. The rule states: "Multiple lines of computational evidence suggest no impact on gene or gene product." The evidence for this variant shows: CADD score 3.19 (benign range) and SpliceAI max score 0.21 (below threshold for splicing impact). Therefore, this criterion is applied at Supporting strength because computational evidence supports benign effect.

BP5

BP5 (Not Applied)

According to standard ACMG guidelines: BP5 applies when variant found in a case with an alternate molecular basis. The evidence for this variant shows: no such case data. Therefore, this criterion is not applied.

BP6

BP6 (Not Applied)

According to standard ACMG guidelines: BP6 applies when a reputable source classifies variant as benign without evidence. The evidence for this variant shows: no such external classification. Therefore, this criterion is not applied.

BP7

BP7 (Not Applied)

According to VCEP guidelines: BP7 applies to synonymous or deep intronic variants (>±40 from splice sites). The evidence for this variant shows: location c.6808-11 is within 40 nucleotides of acceptor site. Therefore, this criterion is not applied.